Sep 10, 2019 by Brian Orelli, PhDTurns Out, It Wasn't Bad News for Intra-Cellular TherapiesDown over 18%, the biotech bounces back.
Sep 5, 2019 by Brian Orelli, PhDHere’s Why Align Technology Dropped 12.4% in AugustInvestors continue to worry about decelerating growth at the orthodontic-device specialist.
Sep 5, 2019 by Brian Orelli, PhDIs the FDA Out to Get This $2.9 Billion Diabetes Drug Class?It’s rejected a pair of drugs in the last six months.
Sep 5, 2019 by Brian Orelli, PhDHere's Why Alexion Pharmaceuticals Dropped 11% in AugustIt was a roller coaster of a month for the biotech.
Sep 4, 2019 by Brian Orelli, PhDHere's Why Nektar Therapeutics Plummeted 38% in AugustManufacturing issues plague the start-up.
Sep 4, 2019 by Brian Orelli, PhDHere's Why TherapeuticsMD Jumped 34% in AugustThe women’s health expert logged a solid second quarter.
Sep 3, 2019 by Brian Orelli, PhDHere's How Emergent BioSolutions Procured a Higher Price TodayThe U.S. government wants more of its smallpox vaccine.
Aug 28, 2019 by Brian Orelli, PhDTrump Wants the VA to Get as Much of This Drug as It CanHow much Johnson & Johnson will actually benefit is unclear.
Aug 26, 2019 by Brian Orelli, PhDHere’s Why The Medicines Company Shares Jumped 13.8% TodayThe biotech got good news on a clinical trial.
Aug 19, 2019 by Brian Orelli, PhDWhy Mallinckrodt and Endo International Shares Jumped TodayInvestors appear to have some confidence that the companies will settle their opioid lawsuits.
Aug 15, 2019 by Brian Orelli, PhDHere's Why Mallinckrodt Dropped 12% TodayPositive clinical-trial results couldn't save the embroiled biotech.
Aug 15, 2019 by Brian Orelli, PhDNovo Nordisk Waits for Its Next LaunchThe second quarter wasn't too shabby either.
Aug 14, 2019 by Brian Orelli, PhDDiplomat Pharmacy Considers Its OptionsThe company is undergoing a review of strategic alternatives.
Aug 14, 2019 by Brian Orelli, PhDIonis Pharmaceuticals Looks to Partners to Pay the BillsRoyalties are nice, but licensing, milestone, and option payments are getting it done for this biotech.
Aug 13, 2019 by Brian Orelli, PhDBecton, Dickinson Accelerates Its GrowthThe medical device maker looks to round out its fiscal year with a bang.
Aug 12, 2019 by Brian Orelli, PhDAlnylam Adds on Sales, Looks to Pipeline for Further GrowthThe biotech could go from one to four marketed drugs in a little over a year.
Aug 7, 2019 by Brian Orelli, PhDbluebird bio Prepares for LaunchZynteglo was recently approved in Europe.
Aug 7, 2019 by Brian Orelli, PhDGenomic Health's Second Quarter Was So Great It Got the Company AcquiredExact Sciences takes out the cancer-test maker for $2.8 billion.
Aug 6, 2019 by Brian Orelli, PhDCelgene Continues Growing While Waiting for its Acquisition to CloseBristol-Myers is getting an even bigger cash cow.
